Covid-19 roundup: Cure­Vac, GSK de­but sec­ond shot at pan­dem­ic vac­cine; BioN­Tech ex­pands Covid-19 tri­al

Cure­Vac flamed out on its first at­tempt at pro­duc­ing a suc­cess­ful Covid-19 vac­cine last June and the Ger­man biotech chalked up a sec­ond-gen ap­proach with part­ner Glax­o­SmithK­line as a sav­ing grace in Oc­to­ber.

As Omi­cron’s sis­ter vari­ant takes over as the dom­i­nant strain in the US, Cure­Vac said Wednes­day it has be­gun dos­ing pa­tients in the first hu­man tri­al of its sec­ond go at an mR­NA jab for the pan­dem­ic. Da­ta from the tri­al are ex­pect­ed to show how well the new vac­cine can stand up against Covid-19 vari­ants and oth­er pathogens, mean­ing Cure­Vac doesn’t want this to be a one-and-done.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER